AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01249118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0973 Oral Capsules
Description: Oral dose.
Study NCT04564118 — intervention group
Intervention type: DRUG
Intervention: Retrospective analysis of assigned treatment
Description: analysis of treatment assigned by physicians within routine clinical practice
Study NCT04211805 — intervention group
Intervention type: DRUG
Intervention: Tenofovir Alafenamide 25 MG for arm (A)
Description: Tenofovir Alafenamide (TAF) will be provided, 25 mg Per Oral daily.
Study NCT04211805 — intervention group
Intervention type: DRUG
Intervention: Tenofovir Disoproxil Fumarate 300mg for arm (B)
Description: Tenofovir Disoproxil Fumarate (TDF) will be provided, 300 mg Per Oral daily.
Study NCT01728480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entolimod
Description: Given SC
Study NCT01728480 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Undergo IMRT
Study NCT01728480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT04834765 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-based art therapy
Description: The researchers developed a novel MBAT intervention consisting of 10 easily reproducible, clay-based MBAT directives, administered through an online platform delivery strategy. By developing an MBAT intervention that uses an online delivery strategy, the researchers realized it may have the potential of decreasing demands placed on counseling centers.
Study NCT04834765 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Art-only
Description: The AO modules consist of an open-ended art-making exercise, with minimal direction. The AO intervention is designed as an 'art for art's sake' intervention with the focus on the art-making and less on outcome or product. Participants are asked to pull their ball of clay out and spend ten minutes creating a form from the clay to visually express their experience in the present moment.
Study NCT04834765 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-only
Description: The MO modules consist of only the mindfulness practices from the ABM intervention. The participants to follow along with a five-minute light yoga sequence, where asanas (yoga postures) are cued with breath. Yoga, for the purposes of the study, is explicitly defined to participants as the unity of breath with body movement. Poses were chosen based on their accessibility to a variety of body types and abilities, and chosen because they are documented to aid in grounding, increased haptic awareness, lowered levels of stress and anxiety, and restoration.
Study NCT00526877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Risperidone long-acting injectable 25 milligram (mg) or 37.5 mg or 50 mg will be administered intramuscularly (into a muscle) depending on Investigator's discretion every 2 weeks for 24 weeks.
Study NCT02609698 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coroflex ISAR
Description: This stent platform has a thin-strut cobalt-chromiun alloy backbone, no polymer, microporous surface.
Study NCT02609698 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coroflex ISAR
Description: This stent platform has a thin-strut cobalt-chromiun alloy backbone, no polymer, microporous surface.
Study NCT02609698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 months DAPT
Study NCT02609698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6 months DAPT
Study NCT02268851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TGR-1202
Description: Capsules taken whole daily with water and with food
Study NCT02268851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Capsules taken whole with water- Do not consume fish oil, vitamin E, grapefruit, or Seville oranges
Study NCT03977610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-68 PSMA ligand
Description: For PSMA PET/CT scan, the subject will have catheter(s) placed for intravenous administration of \[68Ga\]PSMA-11. Subjects will receive a single intravenous bolus of 2-5 mCi \[68Ga\]PSMA-11 and received PET/CT scan 60 minutes later. Patient will underwent two times of PSMA-11 PET/CT scans before and under androgen deprivation therapy within a 10-14 weeks interval.
Study NCT04428593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treamid 5 mg
Description: The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.
Study NCT04428593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treamid 15 mg
Description: The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.
Study NCT04428593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treamid 50 mg
Description: The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.
Study NCT04428593 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.
Study NCT03813251 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ForConti Contix Fecal Incontinence Management System (FIMS)
Description: Use the device for up to 12 hours per use for 4 weeks
Study NCT04023474 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet Rich Fibrin (PRF) Application
Description: Platelet Rich Fibrin application to flap defect.
Study NCT03614780 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 30 minutes outdoors
Description: Participants were asked to add an additional 30 minutes of time spent outdoors during the last 5 days of participation
Study NCT02125474 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [177Lu] DOTA-TATE
Description: We have designed a one-arm phase II prospective sequential clinical trial to assess the therapeutic efficacy of 177-Lu-\[DOTA 0, Tyr 3\] octreotate (177-Lu- DOTATATE) applied intravenously in three separate doses to patients with inoperable progressive WDNET.
Study NCT03092804 — intervention group
Intervention type: PROCEDURE
Intervention: ventriculo-peritoneal shunting
Description: A mainstream therapy for NPH. It involves the device of CSF flow control of shunts and accessories(CFDA(I)20143665605)
Study NCT01208831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225
Study NCT04535167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07304814
Description: PF-07304814 is an anti-viral, formulated for intravenous delivery
Study NCT04535167 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be formulated for intravenous delivery
Study NCT02133014 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic-assisted percutaneous catheter drainage
Description: Removing necrotic pancreatic organizations and putting the catheter around the region of pancreas.After the surgery,patient's cavity are continuously douched by catheter using 0.5% 5-fluorouracil normal saline
Study NCT03329781 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BCM-95
Description: Consuming 1 capsule of BCM-95 per day.
Study NCT03329781 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Consuming 1 placebo capsule per day
Study NCT03177915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hylase
Description: median nerve hydro-dissection using Hyalase + 10 cc saline injection
Study NCT02133014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% 5-fluorouracil normal saline
Description: On the one hand,0.5% 5-fluorouracil normal saline directly inhibit DNA synthesis of pancreatic acinar cells which result in the synthesis of amylopsin of and trypsase is restrained.On the other hand,it can induce pancreatic cells apoptosis and alleviate pancreatic necrosis.
Study NCT01596543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: partial and complete sleep deprivation
Description: The subjects will visit our labs 4 times. The second visit will be used as the experimental control. During the third and fourth visits the subject will go through an exercise heat tolerance test and a measurement of their physiological efficiency after a partial and complete sleep deprivation, respectively.
Study NCT04387760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 400mg BID PO day 1 then 200mg BID PO from day 2 to day 10.~In addition to Hydroxychloroquine all patients will receive the standard care (according to local Bahrain COVID19 guidelines). Any patient who is fit for discharge, can be discharged and medications will be stopped on discharge.
Study NCT04387760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: 1600mg BID PO day 1600mg BID PO day 2 to day 10.~In addition to Favipiravir all patients will receive the standard care (according to local Bahrain COVID19 guidelines). Any patient who is fit for discharge, can be discharged and medications will be stopped on discharge.
Study NCT04387760 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine care for COVID-19 patients
Description: Supportive care according to local guidelines
Study NCT04387760 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine care for COVID-19 patients
Description: Supportive care according to local guidelines
Study NCT01487473 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-Based Stress Reduction
Description: An 8-week structured group program that was developed to improve psychological and physical symptoms associated with pain. It incorporates a variety of mindfulness meditation exercises including mindful yoga, sitting meditation, and body scan to facilitate attention, acceptance, and awareness of one's experiences.
Study NCT02352922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine
Description: pre-incision infiltration with liposomal bupivacaine
Study NCT02352922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl
Description: pre-incision infiltration with bupivacaine HCl
Study NCT02480907 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Workshop Group
Description: Workshop support group
Study NCT02480907 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-based support group
Description: Internet based support group with E-mail coaching
Study NCT00397943 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK's candidate Mycobacterium tuberculosis vaccine 692342
Description: Intramuscular injection, 2 doses at 0, 1 month
Study NCT00397943 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and adjuvant system
Description: Intramuscular injection, 2 doses at 0, 1 month
Study NCT00397943 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and physiological saline
Description: Intramuscular injection, 2 doses at 0, 1 month
Study NCT03177915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: median nerve hydro-dissection using 10 cc saline injection
Study NCT02268487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Treatment
Study NCT00397943 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Control vaccine with the adjuvant system.
Description: Intramuscular injection, 2 doses at 0, 1 month
Study NCT03718975 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Successor of Phonak Audéo B90
Description: Successor of the most recent Receiver in the canal (RIC) Hearing aid form Phonak which will be fitted to the participants individual Hearing loss.
Study NCT03718975 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phonak Audéo B90
Description: The Phonak Audéo B90 is the most recent Receiver-in-the-canal Hearing aid from Phonak which will be fitted to the participants individual Hearing loss.
Study NCT03551028 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: HPV self collection
Description: The proposed community based participatory study aims to determine whether offering self-collection for HPV testing through the mobile mammography unit is an acceptable and feasible method to increase access to cervical cancer screening for under-screened women in Southwest Virginia.
Study NCT03607734 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Amoxicillin
Description: A graded oral challenge test, using amoxicillin in syrup form, will be administered as follows:~* 50mg amoxicillin (10% total dose)~* 250mg amoxicillin (50% total dose)~* 200mg amoxicillin (remainder needed to complete a 500mg full dose) A 20 minute interval will separate each dose given, and participants will be observed throughout the test. They will be required to stay for one hour after the final dose has been administered. Fully trained staff and all equipment for emergency resuscitation will be immediately available.
Study NCT03741881 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: Participants are treated with their usual prescribed treatment, either given regularly as a prevention (prophylaxis) or when needed (on-demand).
Study NCT02987660 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Topography Guided LASIK
Description: Corneal surgery for refractive error correction
Study NCT03004014 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sleep endoscopy during propofol induced sleep
Description: It will be performed a sleep endoscopy during drug induced sleep endoscopy
Study NCT02987660 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Small Incision Lenticular Extraction
Description: Refractive surgical procedure for the correction of myopia with or without astigmatism
Study NCT02987660 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WaveLight EX500 Excimer Laser System
Description: As used for corneal stroma ablation (refractive error correction). The treatment is intended to last the subject's lifetime.
Study NCT02987660 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VisuMax Surgical Laser
Description: As used for lenticule creation/removal (refractive error correction). The treatment is intended to last the subject's lifetime.
Study NCT01756976 — intervention group
Intervention type: DEVICE
Intervention: OrthoPat Advance
Description: The device will be used initially in hysterectomy procedures. After a confirmation of product quality, the device will be used in routine orthopedic procedures.
Study NCT06298097 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Connectivity measures
Description: Electroencephalography connectivity measures will be collected and compared in both stroke patients and healthy participants. Connectivity measures will be extracted using these devices: high-density electroencephalography (using either a 128-channel or a 256-channel system) and magnetic resonance imaging.
Study NCT03110822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Oral Tablet [Jakafi]
Description: Ruxolitinib will be administered on days 1-28 of the treatment cycle.
Study NCT03110822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered on Days 1-21 of the treatment cycle.
Study NCT03110822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methyl-prednisolone will be administered on Days 1-28 of the treatment cycle.
Study NCT01754896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mailing of FIT kit directly to patient
Description: Patient receives a mailed invitation to participate in CRC screening, with a FIT screening kit included.
Study NCT01754896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mailed invitation to pick up lab requisition and then kit
Description: Patients receives a mailed invitation to visit their physician to discuss CRC screening. At that visit, they would receive a FIT laboratory requisition, which they will take to a local lab patient service centre to pick up a FIT kit.
Study NCT01754896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mailing completed kits in for processing
Description: Patients mails completed kit in for processing using postage-paid reply envelope provided.
Study NCT01754896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dropping completed kits at lab for processing
Description: Patient takes completed FIT in to lab patient service centre for processing.
Study NCT02943551 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Online Tutorial
Description: For each group of practices, during the first month of intervention participation, study staff at Seattle Children's Research Institute will send each participating provider within a group/wedge, via email, a password to access the online tutorial. Participants will be asked to view the 40-minute tutorial at a time that is convenient for them but prior to the first webinar. Investigators will be able to track whether and how often participants access the online tutorial as a measure of engagement in the intervention. PROS will follow up, via email or phone, with providers who have not completed the tutorial within a three week timeframe.
Study NCT02943551 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Webinars
Description: The first webinar, focused on making appropriate antibiotic choices for bacterial ARTIs, will be held at the beginning of month 2 of intervention participation, and the second webinar, focused on recommended communication practices during visits for ARTIs, will be held at the beginning of month 3 of intervention participation. Due to webinar faculty time constraints, we will establish dates/times for the webinar prior to recruitment. Providers will be given information on webinar dates in both the randomization email, as well as include the dates in the study box letter.~The webinars will be recorded to facilitate attendance for those who are unable to make the scheduled date/time. Included in the recording will be the presentation and any questions and answers from participants.
Study NCT02943551 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Booster Sessions
Description: An online link to the first booster video vignette will be sent to practice participants via email at the beginning of month 5 of intervention participation for each group/wedge. The link will lead to a website in which the provider will need to create a user name and password to access the booster videos. Two additional booster vignettes will be made available for viewing at the beginning of months 7 and 9 of intervention participation.~For each of the three booster sessions, up to three reminders to complete viewing the video vignette will be sent over a 2-week period. The study team will be able to monitor whether participants access and complete the questions at the end of each vignette.
Study NCT01728480 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01728480 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03106545 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposome bupivacaine
Study NCT03518749 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1mA tDCS
Description: transcranial direct current stimulation with the intensity of 1mA
Study NCT03518749 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2mA tDCS
Description: transcranial direct current stimulation with the intensity of 2mA
Study NCT03106545 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Liposome bupivacaine
Study NCT03106545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome bupivacaine
Study NCT02177617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox injection
Description: Participants will receive a tailored dose of Botox to address their Cervical Dystonia symptoms
Study NCT02177617 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Participants will undergo physical therapy sessions with a physical therapist trained in movement disorders. Participants will be instructed to continue these exercises five times per week, and will be called weekly by the investigator to check progress.
Study NCT02177617 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation (TMS)
Description: For these tests, participants will sit in a chair that looks like one found at the dentist's office. A nerve stimulator will be placed on the wrist of the right hand to stimulate the median and ulnar nerves. The intensity of the nerve stimulator will be gradually increased until the right thumb begins to twitch. A magnetic coil will be placed on the scalp on the left side of the head, overlying the brain's motor cortex, to stimulate the brain's output to the muscles in the opposite hand. This procedure will be repeated using the left wrist and the right side of the head.
Study NCT03518749 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive control training
Description: cognitive control training with the PASAT
Study NCT03518749 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive control training
Description: cognitive control training with the PASAT
Study NCT02017600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-420
Description: ND-420 50 mg/m2 on day1